NASH Treatment Focus Akero Therapeutics is developing transformational treatments for non-alcoholic steatohepatitis (NASH), an area with a significant market need as there are currently no approved therapies for this disease. This presents a sales opportunity for Akero to cater to the unmet medical needs of NASH patients.
Clinical-Stage Product EFX Akero's lead product candidate, EFX, is an engineered Fc-FGF21 fusion protein currently in a Phase 2b clinical trial for NASH treatment. As EFX progresses through clinical trials, there is a potential sales opportunity for partnerships, licensing deals, or future commercialization strategies upon successful regulatory approvals.
Investigation Impact Recent legal issues and class action lawsuits faced by Akero, related to significant losses and potential violations of securities laws, may impact investor confidence and stock performance. Sales teams need to be aware of these issues and their potential implications on business relationships and investment opportunities.
Market Expansion The launch of the Phase 2b SYMMETRY study indicates Akero's commitment to advancing its clinical research for NASH treatment. This expansion of clinical trials and research efforts presents a sales opportunity for partnerships with healthcare institutions, research organizations, and potential investors looking to support innovative therapies.
Financial Health & Funding With reported revenue in the range of $0-$10M and total funding of $367M, Akero has the financial resources to support its research and development activities. Business development professionals can leverage Akero's financial stability to negotiate strategic collaborations, investments, or acquisitions that align with the company's growth objectives and market positioning.
1-888-653-2347 
support@leadiq.com 
